GO
Loading...

Novartis AG

More

  • CHICAGO, July 21- All too often, I see investors heading in the wrong direction en masse. The Energy SPDR, which charges 0.16 percent for annual management expenses and holds Exxon Mobil Corp, Chevron Corp and Schlumberger NV, has climbed 22 percent in the past 12 months, with nearly one-third of that gain coming in the three months through July 18.

  • July 18- Catalent Inc, controlled by Blackstone Group LP, said it expects its initial public offering to be priced between $19 and $22 per share, valuing the company at about $2.57 billion at the top end. The company's major customers include Pfizer Inc, Johnson& Johnson, GlaxoSmithKline Plc, Merck& Co Inc and Novartis AG.

  • *Earnings pin back Sandvik, SGS. EDINBURGH, July 17- European stocks fell on Thursday, with appetite for equities dented by new Western sanctions on Russia and a mixed earnings picture. Stocks with high exposure to Russia were among the top fallers after the European Union and the United States increased sanctions on the country.

  • ZURICH, July 17- Swiss drugmaker Novartis posted a quarterly rise in sales that missed expectations and said it would focus on eking out gradual cost savings to boost margins as it prepares a radical business overhaul.

  • EDINBURGH, July 17- European stocks fell on Thursday, weighed down by mixed earnings reports after posting their best gains in three months in the previous session, while new Western sanctions on Russia also hit stocks exposed to the country.

  • Early movers: JPM, GS, JNJ, LO, TWX, TWTR & more Tuesday, 15 Jul 2014 | 8:09 AM ET
    Traders work on the floor of the New York Stock Exchange in New York.

    Some of the names on the move ahead of the open.

  • ZURICH, July 15- Swiss drugmaker Novartis has struck an agreement with Google to develop "smart" contact lenses that would help diabetics track their blood glucose levels or restore the eye's ability to focus. The device for diabetics would measure glucose in tear fluid and send the data wirelessly to a mobile device, Novartis said.

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • Will earnings tell the story markets need to hear? Sunday, 13 Jul 2014 | 6:21 PM ET
    Traders work the floor of the New York Stock Exchange before the closing bell in New York.

    Quarterly earnings growth and clues from companies' commentaries will tell whether there really will be a bounce back in growth in the second half.

  • Allergan to shareholders: Ignore Pershing Square Friday, 11 Jul 2014 | 6:31 PM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.

  • *France's Servier, Israel's Teva among those fined. BRUSSELS, July 9- European Union antitrust regulators fined French drugmaker Servier, Israel's Teva and four others a total of 428 million euros on Wednesday, as they crack down on deals which block cheaper generic medicine.

  • *EU shift to Avastin a threat to Novartis, Bayer profits. PARIS, July 8- French lawmakers voted on Tuesday to allow the use of Roche's cancer drug Avastin as a cheap alternative eye treatment, in a budget-minded move critics fear could put patients' health- and company profits- at risk.

  • TEL AVIV, July 3- Teva Pharmaceutical Industries has filed a so-called citizen petition with the U.S. Food and Drug Administration, aiming to delay cheap generic competition to Copaxone, its top-selling treatment for multiple sclerosis.

  • FRANKFURT, July 1- German drugmaker Bayer said it would keep the Dr. Scholl's and Coppertone- each worth more than $1 billion- Bayer said it was not planning to untie the Merck bundle it secured in May in a competitive bidding tussle with Reckitt Benckiser, Procter& Gamble Co and Novartis.

  • Early movers: NFLX, WYNN, APP & more Tuesday, 1 Jul 2014 | 7:56 AM ET

    Some of the names on the move ahead of the open.

  • FRANKFURT, July 1- German drugmaker Bayer said it would keep the Dr. Scholl's and Coppertone- each worth more than $1 billion- Bayer said it was not planning to untie the Merck bundle it secured in May in a competitive bidding tussle with Reckitt Benckiser, Procter& Gamble Co and Novartis.

  • TOKYO, July 1- Tokyo prosecutors said on Tuesday they will charge the Japanese unit of Novartis AG and a former employee in connection with allegations of data manipulation in promoting its best-selling blood pressure drug Diovan.

  • WASHINGTON/ MUMBAI, June 27- India's Ranbaxy Laboratories Ltd has received approval from the U.S. Food and Drug Administration to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment.

  • *Move bolsters Shire in defence against AbbVie. *AbbVie to put its case to Shire shareholders- source. LONDON, June 25- Shire, which has spurned a $46 billion takeover offer from U.S. group AbbVie as inadequate, has a new reason to argue it is worth more after a U.S. court backed patent claims on its top-selling drug Vyvanse.

  • *European Commission declines to comment. BRUSSELS, June 19- EU antitrust regulators are set to fine French drugmaker Servier, Israel's Teva and several of their peers next month for blocking cheaper generic medicine, two people with knowledge of the matter said on Thursday.